MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 84 filers reported holding MERSANA THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $250,787 | -1.2% | 197,470 | +219.6% | 0.00% | 0.0% |
| Q1 2023 | $253,957 | -15.1% | 61,790 | +21.0% | 0.00% | 0.0% |
| Q4 2022 | $299,241 | -60.7% | 51,065 | -54.6% | 0.00% | -75.0% |
| Q3 2022 | $761,000 | -0.9% | 112,525 | +242.6% | 0.00% | 0.0% |
| Q2 2020 | $768,000 | +486.3% | 32,840 | +46.6% | 0.00% | +300.0% |
| Q1 2020 | $131,000 | – | 22,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 1,191,271 | $6,980,848 | 6.79% |
| Bain Capital Life Sciences Investors, LLC | 8,663,673 | $50,769 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 950,000 | $5,567,000 | 3.43% |
| Sarissa Capital Management LP | 3,997,010 | $23,422,479 | 2.79% |
| Decheng Capital Management III (Cayman), LLC | 904,268 | $5,299,010 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 1,140,182 | $6,681,467 | 1.91% |
| Orbimed Advisors | 9,011,437 | $52,807,021 | 1.01% |
| Opaleye Management Inc. | 460,000 | $2,695,600 | 0.94% |
| Artal Group S.A. | 2,200,000 | $12,892 | 0.72% |
| DAFNA Capital Management LLC | 413,463 | $2,422,893 | 0.68% |